Mangalam Drugs & Organics Limited Share Price

Equities

MANGALAM

INE584F01014

Pharmaceuticals

Delayed Bombay S.E. 08:59:22 26/06/2024 BST 5-day change 1st Jan Change
107 INR +0.05% Intraday chart for Mangalam Drugs & Organics Limited -0.65% +8.92%

Financials

Sales 2022 4.48B 53.56M 4.23B Sales 2023 3.7B 44.3M 3.49B Capitalization 1.55B 18.53M 1.46B
Net income 2022 197M 2.36M 186M Net income 2023 12M 144K 11.33M EV / Sales 2022 0.56 x
Net Debt 2022 859M 10.28M 811M Net Debt 2023 859M 10.27M 811M EV / Sales 2023 0.65 x
P/E ratio 2022
8.28 x
P/E ratio 2023
122 x
Employees 523
Yield 2022 *
-
Yield 2023
-
Free-Float 45.3%
More Fundamentals * Assessed data
Dynamic Chart
Mangalam Drugs & Organics Limited agreed to acquire Shri JB Pharma LLP. CI
Mangalam Drugs & Organics Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Mangalam Drugs & Organics Limited Reports Earnings Results for the Half Year Ended September 30, 2023 CI
Mangalam Drugs & Organics Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Mangalam Drugs & Organics Limited Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Mangalam Drugs & Organics Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023 CI
Mangalam Drugs & Organics Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Mangalam Drugs & Organics Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022 CI
Mangalam Drugs & Organics Limited Reports Earnings Results for the First Quarter Ended June 30, 2022 CI
Mangalam Drugs & Organics Limited Reports Earnings Results for the Full Year Ended March 31, 2022 CI
Mangalam Drugs & Organics Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2022 CI
Mangalam Drugs & Organics Limited Announces Appointment of Shri Rakesh K. Milwani as an Additional Director (Non- Executive Non- Independent Director) CI
Mangalam Drugs & Organics Limited Announces Executive Changes CI
Mangalam Drugs & Organics Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021 CI
Mangalam Drugs & Organics Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021 CI
More news
1 day+0.05%
1 week-0.65%
Current month+5.21%
1 month+0.28%
3 months+10.20%
6 months+8.29%
Current year+8.92%
More quotes
1 week
105.00
Extreme 105
110.00
1 month
96.10
Extreme 96.1
117.80
Current year
85.16
Extreme 85.16
132.40
1 year
85.16
Extreme 85.16
132.40
3 years
85.16
Extreme 85.16
196.50
5 years
20.40
Extreme 20.4
196.50
10 years
8.15
Extreme 8.15
441.50
More quotes
Managers TitleAgeSince
Chief Executive Officer 70 15/04/96
Director of Finance/CFO - -
Compliance Officer 30 07/02/22
Members of the board TitleAgeSince
Chief Executive Officer 70 15/04/96
Director/Board Member 69 20/03/21
Director/Board Member 72 04/02/15
More insiders
Date Price Change Volume
26/06/24 107 +0.05% 5 778
25/06/24 106.9 +0.80% 3,244
24/06/24 106 -0.24% 3,233
21/06/24 106.3 -1.12% 623
20/06/24 107.5 -0.14% 5,165

Delayed Quote Bombay S.E., June 26, 2024 at 08:59 am

More quotes
Mangalam Drugs and Organics Limited is an India-based manufacturer of active pharmaceutical ingredients (APIs) and intermediates. Under the Company's Fight Malaria Program, it supplies anti-malaria APIs worldwide. Its products include API, intermediates and specialty chemicals. Its API products include acyclovir, amodiaquine, artemether, artesunate, atazanavir sulfate, bisoprolol fumarate, chloroquine phosphate, furosemide and dolutegravir sodium. The Company's intermediates products include 4,6-Dichloro-5-Methoxy Pyrimidine; 4,7- dichloroquinoline; ortho phenoxy methane sulfonanilide; tenofovir alafenamide base, and tenofovir disoproxil base. Its specialty chemicals products include L (+)-menthol; 2,3-dihydrophthalazine-1,4-dione or phthalazine-1,4-dione, and 4-cynoethyl-2-methyl phenol. Its pipeline APIs (under development) include Ganaplacide (IH), Tafenoquine Succinate (IH) and Pretomanid (IH). Its pipeline APIs (developed at research and development) is Bictegravir Na (IH).
More about the company
  1. Stock Market
  2. Equities
  3. MANGALAM Stock